Current and future players in the osteoarthritis market

Osteoarthritis market (OA) is a slowly progressing joint disease that is the second leading cause of disability and discomfort in the elderly, behind cardiovascular disease. The OA area is distinguished by a high level of unmet clinical need, which is exacerbated by the poor efficacy of presently available analgesics and the lack of disease-modifying OA medicines (DMOADs). Current OA standards of care (SOCs) are symptom-focused and rely on generic medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, and intra-articular (IA) injections. There are presently no disease-modifying medicines authorized for OA.
A few businesses dominate the illness sector, with the therapy paradigm consisting primarily of off-label generic medications. Novartis with Voltaren (diclofenac) and Bayer with naproxen are two notable important participants in the NSAID OA market. Because of duloxetine, Eli Lilly is another important participant in the OA market. While these medications will continue to play a role in the OA treatment industry, sales are likely to decline owing to generic competition. Similarly, significant participants in the opioid OA market, like as Janssen with Ultram, are projected to suffer revenues decline owing to decreased opioid prescriptions globally.

read more..